Qualia NAD+(R) Increases NAD+ In Human Participants: A Randomized, Double-Blind, Placebo-Controlled Study

Abstract

Nicotinamide adenine dinucleotide (NAD) is a crucial coenzyme involved in cellular energy homeostasis whose levels decline notably with aging, which has prompted interest in NAD+ boosting to combat age-related diseases and dysfunction. Numerous clinical trials have demonstrated safety and efficacy for B3 vitamins like nicotinamide riboside (NR) to increase NAD+ levels and augment the NAD+ metabolome. Limited impact on clinically relevant outcomes or quality of life have been demonstrated, however. This randomized, double-blind, placebo-controlled study examined the effects of Qualia NAD+(R) on whole blood NAD+ levels and quality of life measures. Twenty-five healthy adults aged 40 - 65 (56% female) consumed Qualia NAD+ (n = 9) or placebo (n = 16) for 28 consecutive days. NAD+ levels were measured using a novel self-administered, non-invasive blood spot assay test conducted at baseline and at study end, while quality of life measures were reported bi-weekly. Overall, Qualia NAD+ significantly increased NAD+ levels an average of 74% compared to a 4% increase observed in the placebo group (p < 0.001). Within-groups comparisons for Qualia NAD+, and changes in NAD+ levels comparing Qualia NAD+ and placebo were also significant (p < 0.001). Improvements in the overall and sexual categories (p = 0.02 and p = 0.04) were observed for males only comparing baseline to day 28, while no other quality of life changes were noted. Qualia NAD+, a novel nutraceutical formulated with multiple vitamins, nutrients, and botanical compounds, effectively increased whole blood NAD+ levels and improved some symptoms of aging in males. Clinicaltrials.gov identifier: NCT06812416.